Drugs / Tecogalan Sodium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002137 | — | HIV infectious disease, Kaposi's sarcoma | Daiichi Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tecogalan Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002137 ↗ |
| Known as | DS-4152 | “A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4” NCT00002137 ↗ |
| Route | Intravenous | “Patients receive intravenous DS-4152 by infusion weekly for 4 weeks” NCT00002137 ↗ |